Printed From:

Two starting doses

  • SOLIQUA 100/33 is delivered subcutaneously, via the SOLIQUA 100/33 SoloStar® pen, once daily within one hour prior to the first meal of the day
  • Use alternative treatments if doses below 15 Units or above 60 Units are required

*Starting dosage is based on current dose of basal insulin.

15 Units is the recommended starting dose for patients uncontrolled on lixisenatide, a GLP-1 RA.

One Unit of SOLIQUA 100/33 contains 1 Unit of Lantus® and 0.33 mcg of lixisenatide.

Titration instructions

Titrate by 2-4 units every week until target fasting plasma glucose (FPG) is reached.

SOLIQUA 100/33 is to be dosed based on the patient's metabolic needs, blood glucose monitoring results, and glycemic goals.

  • The dose on the SOLIQUA 100/33 SoloStar® pen can be adjusted in 1-Unit increments
Familiar routine for your patients
Once-daily administration Within one hour prior to first meal of the day
One co-pay for 2 medicines
One familiar pen technology